Arsenic trioxide and microrna-204 display contrary effects on regulating adipogenic and osteogenic differentiation of mesenchymal stem cells in aplastic anemia

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 10, 2014, Pages 885-893

  Zhao, Junmei ^a   Wang, Chao ^a   Song, Yongping ^a   Fang, Baijun ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Adipogenic differentiation; Aplastic anemia; Arsenic trioxide; Mesenchymal stem cells; MiR 204; Osteogenic differentiation

Indexed keywords

ARSENIC TRIOXIDE; MICRORNA; MIRN204 MICRORNA, HUMAN; ORGANOARSENIC DERIVATIVE; OXIDE; PRIMER DNA; RUNX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RUNX2;

ADIPOSE TISSUE; APLASTIC ANEMIA; BIOSYNTHESIS; BONE MARROW CELL; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; HUMAN; IMMUNOPHENOTYPING; MESENCHYMAL STROMA CELL; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADIPOSE TISSUE; ANEMIA, APLASTIC; ARSENICALS; BASE SEQUENCE; BONE MARROW CELLS; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DNA PRIMERS; HUMANS; IMMUNOPHENOTYPING; MESENCHYMAL STROMAL CELLS; MICRORNAS; OXIDES;

EID: 84924813229     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmu082     Document Type: Article

References (41)

1. Maciejewski JP, Selleri C, Sato T, Anderson S and Young NS. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood 1996, 88:1983-1991.
2. Scopes J, Ismail M, Marks KJ, Rutherford TR, Draycott GS, Pocock C and Gordon-Smith EC, et al. Correction of stromal cell defect after bone marrow transplantation in aplastic anaemia. Br J Haematol 2001, 115:642-652.
3. Killick SB, Cox CV, Marsh JC, Gordon-Smith EC and Gibson FM. Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti-thymocyte globulin: examination of the role of the Fas-Fas-L interaction. Br J Haematol 2000, 111:1164-1169.
4. Shipounova IN, Petrova TV, Svinareva DA, Momotuk KS, Mikhailova EA and Drize NI. Alterations in hematopoietic microenvironment in patients with aplastic anemia. Clin Transl Sci 2009, 2:67-74.
5. Lazennec G and Jorgensen C. Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells 2008, 26:1387-1394.
6. Chen YH, Yeh FL, Yeh SP, Ma HT, Hung SC, Hung MC and Li LY. Myocyte enhancer factor-2 interacting transcriptional repressor (MITR) is a switch that promotes osteogenesis and inhibits adipogenesis of mesenchymal stem cells by inactivating peroxisome proliferator-activated receptor gamma-2. J Biol Chem 2011, 286:10671-10680.
7. Hoshiba T, Kawazoe N and Chen G. The balance of osteogenic and adipogenic differentiation in human mesenchymal stem cells by matrices that mimic stepwise tissue development. Biomaterials 2012, 33:2025-2031.
8. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG and Ross J, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425:836-841.
9. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ and Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001, 20:7146-7153.
10. Fu HY, Shen JZ, Wu Y, Shen SF, Zhou HR and Fan LP. Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylationsilenced CDKN2B/CDKN2A genes in human hematologic malignant cells. Oncol Rep 2010, 24:335-343.
11. Cheng H, Qiu L, Zhang H, Cheng M, Li W, Zhao X and Liu K, et al. Arsenic trioxide promotes senescence and regulates the balance of adipogenic and osteogenic differentiation in human mesenchymal stem cells. Acta Biochim Biophys Sin (Shanghai) 2011, 43:204-209.
12. Song Y, Li N, Liu Y and Fang B. Improved outcome of adults with aplastic anaemia treated with arsenic trioxide plus cyclosporin. Br J Haematol 2013, 160:266-269.
13. Li N, Song Y, Zhou J and Fang B. Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia. J Hematol Oncol 2012, 5:61.
14. Hummel R, Hussey DJ and Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010, 46:298-311.
15. Visone R and Croce CM. MiRNAs and cancer. Am J Pathol 2009, 174:1131-1138.
16. Gangaraju VK and Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 2009, 10:116-125.
17. Huang J, Zhao L, Xing L and Chen D. MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem Cells 2010, 28:357-364.
18. Bork S, Horn P, Castoldi M, Hellwig I, Ho AD and Wagner W. Adipogenic differentiation of human mesenchymal stromal cells is down-regulated by microRNA-369-5p and up-regulated by microRNA-371. J Cell Physiol 2011, 226:2226-2234.
19. Mizuno Y, Yagi K, Tokuzawa Y, Kanesaki-Yatsuka Y, Suda T, Katagiri T and Fukuda T, et al. miR-125b inhibits osteoblastic differentiation by downregulation of cell proliferation. Biochem Biophys Res Commun 2008, 368:267-272.
20. Wang FE, Zhang C, Maminishkis A, Dong L, Zhi C, Li R and Zhao J, et al. MicroRNA-204/211 alters epithelial physiology. FASEB J 2010, 24:1552-1571.
21. Enomoto H, Furuichi T, Zanma A, Yamana K, Yoshida C, Sumitani S and Yamamoto H, et al. Runx2 deficiency in chondrocytes causes adipogenic changes in vitro. J Cell Sci 2004, 117:417-425.
22. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N and Terauchi Y, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004, 113:846-855.
23. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R and Mueller E, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005, 309:1074-1078.
24. Young NS, Calado RT and Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006, 108:2509-2519.
25. Li JP, Zheng CL and Han ZC. Abnormal immunity and stem/progenitor cells in acquired aplastic anemia. Crit Rev Oncol Hematol 2010, 75:79-93.
26. Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M and Fatica A, et al. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol 2008, 36:1035-1046.
27. Tocci A and Forte L. Mesenchymal stem cell: use and perspectives. Hematol J 2003, 4:92-96.
28. Deans RJ and Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000, 28:875-884.
29. Verfaillie CM. Soluble factor (s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation. Blood 1993, 82:2045-2053.
30. Moerman EJ, Teng K, Lipschitz DA and Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004, 3:379-389.
31. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F and Daley GQ. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 2009, 460:259-263.
32. Nuttall ME and Gimble JM. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 2004, 4:290-294.
33. Taichman RS, Reilly MJ and Emerson SG. Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Blood 1996, 87:518-524.
34. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC and Martin RP, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
35. Kachinskas DJ, Phillips MA, Qin Q, Stokes JD and Rice RH. Arsenate perturbation of human keratinocyte differentiation. Cell Growth Differ 1994, 5:1235-1241.
36. Trouba KJ, Wauson EM and Vorce RL. Sodium arsenite inhibits terminal differentiation of murine C3H 10T1/2 preadipocytes. Toxicol Appl Pharmacol 2000, 168:25-35.
37. Tontonoz P, Hu E, Devine J, Beale EG and Spiegelman BM. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 1995, 15:351-357.
38. Wauson EM, Langan AS and Vorce RL. Sodium arsenite inhibits and reverses expression of adipogenic and fat cell-specific genes during in vitro adipogenesis. Toxicol Sci 2002, 65:211-219.
39. Lakshmipathy U and Hart RP. Concise review: microRNA expression in multipotent mesenchymal stromal cells. Stem Cells 2008, 26:356-363.
40. Wojtowicz AM, Templeman KL, Hutmacher DW, Guldberg RE and Garcia AJ. Runx2 overexpression in bone marrow stromal cells accelerates bone formation in critical-sized femoral defects. Tissue Eng Part A 2010, 16:2795-2808.
41. Zhang Y, Xie RL, Croce CM, Stein JL, Lian JB, van Wijnen AJ and Stein GS. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc Natl Acad Sci USA 2011, 108:9863-9868.